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Background: T helper (Th) 17 and regulatory T (Treg) cells play a critical role in the pathogenesis of multiple sclerosis
(MS) disease. Bu Shen Yi Sui Capsule (BSYSC), a traditional Chinese medicine formula, has been used clinically for the
treatment of MS patients in China.
Methods: To evaluate the neuroprotective effects and the underlying mechanisms of BSYSC on MS, experimental
autoimmune encephalomyelitis (EAE) model in C57BL/6 mice was induced with myelin oligodendrocyte glycoprotein
(MOG) 35–55. Th17 and Treg cells and the related cytokines were detected by flow cytometry, ELISA, real-time quantitative
reverse transcription PCR, western blot and immunohistochemistry.
Results: We found that BSYSC improved neurological function, reduced inflammatory cell infiltration and damage to the
axons and myelin in the brain and spinal cord. BSYSC down-regulated markedly the ratio of CD4 + IL-17+/CD4 + CD25 +
FoxP3+ T cells in the spleen, decreased the cytokines of IL-17A, IL-6, IL-23, TGF-beta1 in the brain, and dropped the ratio
of IL-17A and FoxP3 mRNA and protein in the brain or spinal cord at different stages.
Conclusions: The study demonstrated that BSYSC had a strong neuroprotective effect on EAE mice. The protective
mechanisms of BSYSC might be associated with mediating the regulation of Th17/Treg cells.
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Multiple sclerosis (MS) as an inflammatory demyelination
disease in the central nervous system (CNS) is pathologic-
ally characterized by multifocal inflammation, demyelin-
ation, and neuronal damage [1]. Experimental autoimmune
encephalomyelitis (EAE), has similar pathological and
clinical manifestations to human MS, is the optimal animal
model of this disease [2].
A large number of studies have shown the autoimmune
responses of MS or EAE are caused mainly by CD4+ Tcells
and the generation of a T helper (Th) 1/Th2 imbalance [3].
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unless otherwise stated.T (Treg) imbalance is a more critical factor in the
mechanism underlying the neurological dysfunction of
MS/EAE [4]. Th17 cells are a subpopulation of CD4+ T
cells that mediate inflammatory responses, while Treg
cells are a type of negative immune regulatory cells that
mediate immune tolerance. The interactions between
Th17 and Treg cells are regulated by the secretion of
numbers of cytokines such as interleukin (IL)-17 and
transforming growth factor (TGF)-β1, and specific tran-
scription factors, including retinoic acid-related orphan
receptor (ROR) γt and forkhead box P3 (FoxP3) [5-7].
The pro-inflammatory cytokines attack the myelin and
axon, consequently, demyelination and axonal injury
occur and result in the onset of MS/EAE [8].
Current therapeutic medicines for MS include cortico-
steroids and immunosuppressors, such as interferon,
glatiramer acetate and natalizumab, show positive effectsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Thus, prednisone acetate (PA) was selected as the control
drug in the present study. Nevertheless, these therapies
have potentially side-effects [1]. Traditional Chinese
medicine (TCM) can be used to treat the complex
and varied presentations of MS, with few side-effects [10].
Bu Shen Yi Sui Capsule (BSYSC, originally named Erhuang
Capsule) is a yin-nourishing, phlegm-resolving and
blood-activating formula of TCM. The previous clinical
studies showed BSYSC had the ability to markedly reduce
and eliminate symptoms such as limbs weakness and
paresthesia, reduce the frequency and intensity of relapses,
ameliorate side-effects of PA and reduces the dose of
medication required, to improve the qualities of life in MS
patients [11,12]. And it has been approved by the Beijing
Food and Drug Administration as a hospital preparation
(No. 10003).
Our previous studies have demonstrated BSYSC can
regulate Interferon (IFN) -γ and IL-4 production to
balance Th1 and Th2 in the serum, brain and spinal
cord of EAE rats [13-15]. The aim of this study was
to explore the regulatory effects of BSYSC on Th17
and Treg cells. Results showed BSYSC had a strong
neuroprotective effect on EAE mice, which might be
associated with the regulation of Th17/Treg cells.
Methods
Medicines and reagents
PA was purchased from Zhejiang Xianju Pharmaceutical
Co., Ltd. (Zhejiang, China). Myelin oligodendrocyte glyco-
protein peptide (MOG) 35–55 (MEVGWYRSPFSRVVH
LYRNGK; purity was >95%) was synthesized by Beijing
Xuheyuan Biotech Co., Ltd. (Beijing, China). Complete
Freund’ adjuvant (CFA) and pertussis toxin (PTX)
were purchased by Sigma-Aldrich (St. Louis, MO, USA).
Enzyme-linked immunosorbent assay (ELISA) kits for
mouse IL-17A was purchased from eBioScience (San
Diego, CA, USA), mouse IL-23 was from Beijing 4A
Biotech Co., Ltd. (Beijing, China), mouse IL-6 and mouse
TGF-β1 were provided by NeoBioscience Technology Co.
(Beijing, China). Mouse anti-IL-17A PERCP-CY5.5, mouse
anti-CD4 APC, mouse anti-CD25 FITC, anti-mouse/rat
FoxP3 PE, rat IgG isotypecontrol PE, FoxP3 staining buffer
set, phorbol 12-myristate 13-acetate (PMA), ionomycin,
and brefeldin A solution were purchased from BD
PharMingen (San Diego, CA, USA). Rabbit anti-mouse
IL-17A and rabbit anti-mouse FoxP3 were purchased
from Abcam (Cambridge, UK) and Cell Signaling
Technology (Boston, USA), respectively. Rabbit polyclonal
anti-β-tubulin was purchased from Epitomics (Burlingame,
USA). Western blot (WB) kits were purchased from
Applygen Technologies Inc. (Beijing, China). Real-time
quantitative reverse transcription PCR (qRT-PCR) kits and
reverse transcription kits were purchased from TiangenBiotech Co., Ltd. (Beijing, China). PCR primers were syn-
thesized by TaKaRa Biotechnology Co. Ltd (Dalian, China).
Preparation of BSYSC
BSYSC was produced by Beijing Ya Dong Biological
Pharmacy Co., Ltd. (Beijing, China). Validation speci-
mens were deposited at the Brain Disease Laboratory of
the School of Traditional Chinese Medicine, Capital
Medical University, China. BSYSC was composed of
Rehmanniae radix praeparata, Radix Rehmanniae, Radix
Polygoni Multiflori, Radix et Rhizoma Rhei, Leonurus
japonicas Houtt., Bulbus Fritillariae Thunbergii, Hirudo,
Scorpio, Rhiazoma Gastrodiae, Fructus Forsythiae. The
proportions of these herbs were 10:10:10:2:10:6:3:2:3:6.
Bulbus Fritillariae Thunbergii ground into fine pow-
ders. The other nine Chinese herbs were extracted
twice with boiling water (2 h per extraction, with a
total 18-fold volume of purified water). The solutions
were concentrated under reduced pressure at 70°C
into powders, which were mixed with powders of
Bulbus Fritillariae Thunbergii. The resulting mixture
of powders was encapsulated. To ensure the quality
and stability of BSYSC, the active ingredients were
identified by ultra-performance liquid chromatography-
quadrupole-time-of-flight-mass spectrometry (UPLC-
QTOF-MS).
Identification of active ingredients in BSYSC by
UPLC-QTOF-MS
Analysis of the extract was performed by UPLC-QTOF-MS
(SYNAPT G2-S, Waters, UK) with a Waters HSS T3
UPLC C18 column (2.1 mm × 150 mm, internal diam-
eter 1.7 μm) set at 35°C. The mobile phase was water
(0.1% formic acid, phase A) and acetonitrile (phase B)
with a gradient program as follows: 0.0–10.0 min, 95%–
95% A; 10.0–15.0 min, 95%–90% A; 15.0–23.0 min,
90%–84% A; 23.0–38.0 min, 84%–60% A; 38.0–63.0 min,
60%–20%; 63.0–85.0 min, 20%–95% A. The flow rate was
0.3 mL/min. The injection volume was 3 μL. The MS spec-
tra were acquired in positive ion mode with an electro-
spray ionization source (ESI-). The ESI source conditions
were: capillary voltage, 2.50 kV; cone voltage, 40 V; quad-
rupole voltage, 6.0 Bar; ion source temperature, 110°C.
Full-scan spectra were acquired in the mass range m/z
100–1,500 m/z. The compounds identified were loganic
acid, decaffeoyl verbascoside, acteoside, isoacteoside, for-
sythiaside, kaempferol-3-O-α-L-rhamnoside, isorhamnetin-
3-O-rutinoside and quercetin-3,3’-dimethyl ether were
shown in Figure 1, Table 1, respectively.
Quantification of Acteoside and Forsythiasidein in BSYSC
The powder was ultrasonicated (300 W, 40 kHz) in water
for 30 min followed by C18 column chromatography.
The samples were analyzed by UPLC-QTOF-MS. The
Figure 1 Chemical structures of active compounds and UPLC-QTOF-MS chromatogram of BSYSC.
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and forsythiaside (derived from Radix Rehmanniae),
were 0.79 mg/g and 0.63 mg/g, respectively.
Experimental animals
Female C57BL/6 mice (aged 6–8 weeks; weight 16.0-18.0 g)
were purchased from Beijing Vital River Laboratories,
China [certification NO. SCXK (JING) 2006–0009].
The mice were feed in the Center of Laboratory
Animals at Capital Medical University [certification
NO. SYXK (JING) 2010–0020]. The mice were housed
under a 12-hour light/dark cycle in individual ventilated
cages and maintained in a specific pathogen-free
grade environment. The experiments were approved
by the Ethics Committee of Capital Medical University
(No. 2011-X-001).Model establishment and experimental treatment
The mice were randomly divided into four groups:
normal control (NC, n = 25), EAE model (EAE, n = 25),
PA-treated (n = 25) and BSYSC-treated (n = 25). EAE
mice were injected subcutaneously (s.c.) with 0.2 mL
emulsion containing 50 μg MOG35–55 in 100 μL of CFA
and 100 μL of normal saline (NS), followed by intraperi-
toneal (i.p.) injections of 500 ng of PTX on Day 0 and
Day 2 post-induction (PI) [16]. The 3.02 g/kg dose of
BSYSC was shown to be more effective against EAE in
our previous study [17]. In the study, the mice in the
BSYSC-treated EAE group were given oral suspensions of
3.02 g/kg BSYSC once a day for 40 days. The PA-treated
EAE mice were administered PA at a dose of 6 mg/kg. NC
and EAE mice were treated with NS. Neurological func-
tion scores were based on the sum of the disease state for
Table 1 Components of BSYSC identified by UPLC-QTOF-MS
Peak no. Retention time (min) Selected ion Formula Compound Measured mass (m/z) Source of drugs
1 5.42 [M-H]+ C16H24O10 loganic acid 375.1132 Radix Rehmanniae
2 7.96 [M-H]+ C20H30O12 Decaffeoylverbascoside 461.1571 Radix Rehmanniae
3 16.14 [M-H]+ C29H36O15 Acteoside 623.2045 Radix Rehmanniae
4 17.37 [M-H]+ C29H36O15 Isoacteoside 623.2043 Radix Rehmanniae
5 17.64 [M-H]+ C29H36O15 Forsythiaside 623.2072 Radix Rehmanniae
6 27.14 [M-H]+ C21H20O10 Kaempferol-3-O-α-L-rhamnoside 431.0854 Radix Polygoni Multiflori
7 18.16 [M-H]+ C28H32O16 Isorhamnetin-3-O-rutinoside 623.2025 Fructus Forsythiae Suspensae
8 33.14 [M-H]+ C17H14O7 Quercetin-3,3’-dimethyl ether 329.2130 Fructus Forsythiae Suspensae
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in the tail and limbs; scores for the tail were assigned as 1
for paralyzed tail tipparalysis and 2 for tail flaccidity;
scores for the limbs were assigned as 1 for gait disturb-
ance, 2 for moderate paralysis and limb dragging and 3 for
total paralysis. Mortality was assigned a score of 15 [18].
The grip test records down time from glass bar, which
wrapped round gauze to avoid slip of mice. The grip
strength test scores were defined as: 0 for 0–4 s, 1 for
5–9 s, 2 for 10–14 s, 3 for 15–19 s, 4 for 20–24 s, 5 for
25–29 s, and 6 for more than 30 s [19].
Sample collection
The mice were sacrificed on Day 6 (early stage, no
neurological signs), Day 18 (acute stage, neurological
function scores at a peak) and Day 40 (remission stage,
no further increase in the signs of EAE) PI. The spleen
of four mice in each group were removed and prepared
for flow cytometric (FCM) analysis; the brain and spinal
cord were immediately frozen for ELISA, qRT-PCR and
WB analyses; and 4% paraformaldehyde was used to fix
the brain and spinal cord for hematoxylin-eosin (H&E)
staining, transmission electron microscopy (TEM) and
immunohistochemical (IHC) analysis.
Histopathology and ultrastructural pathology
The brain and spinal cord were fixed, embedded in par-
affin, sectioned (thickness, 3 μm) for H&E staining. The
sections were observed with light microscopy (Nikon
Eclipse 80i, Tokyo, Japan). The inflammatory cell infil-
tration was scored as follows: 0, no infiltrate; 1, scattered
inflammatory cells; 2, single inflammatory cells around
blood vessels; 3, inflammatory cell infiltration surround-
ing blood vessels; 4, inflammatory cell infiltration and
perivascular cuff formation, or parenchymal necrosis
[20,21]. Cross-sections (1 mm) of the intumescentia
lumbalis of the brain and spinal cord were embedded in
Epon and sectioned on a Leica EM ultramicrotome.
Thin sections (thickness, 70 nm) were viewed on a TEM
(JEM-1230, Japan) using a digital camera system to ob-
tain micrographs. Ten high-power fields (×10,000) wereselected in the brain (white matter) and spinal cords in
each group. The images were analyzed by Image-Pro
Plus 6.0 (Media Cybernetics, Inc., Washington, USA)
and the results were expressed as area/diameter (mean)
of myelin [22-24].
Intracellular cytokine analysis by FCM
A single cell suspension of spleen mononuclear cells was
first permeabilized with fixation/permeabilzation solu-
tion for 30 min at 4°C, washed in perm/wash buffer, and
then incubated with mouse anti-CD4 APC, mouse anti-
CD25 FITC and mouse anti-FoxP3 PE for 60 min at 4°C.
Alternatively, spleen mononuclear cells were incubated
with mouse anti-CD4 APC, mouse anti-CD25 FITC and
mouse anti-IL-17A PERCP-CY5.5 for 5 hours at 37°C. A
control group treated with isotype control antibody was
prepared. Cells were fixed in formaldehyde and then an-
alyzed on a BD-FACS Calibur (USA). Data were ana-
lyzed based on the percentages of Th17 and Treg cells.
Cytokine measurements by ELISA
The brain of each mouse was weighed and homogenized
with cold NS and centrifuged at 3,000 rpm for 20 min to
obtain supernatants for cytokine ELISA conducted in
strict accordance with instructions provided by the man-
ufacturers. Cytokine (IL-17A, IL-6, IL-23 and TGF-β1)
concentrations were determined using the relevant
standard curves.
mRNA Analysis by qRT-PCR
Total RNA was isolated from approximately 30 mg brain
or spinal cord of mice according to the manufacturer’s
instructions. RNA samples with an OD260/OD280 ratio
of 1.9-2.1 and an OD260/OD230 ratio greater than 2.0
were used for the analysis. The cDNA was synthesized
from total RNA by the reverse transcription of 1 μg of
total RNA using the reverse transcription kit. The pri-
mer sequences for PCR designed by the primer premier
5.0 software, based on the GenBank sequences were as
follows: FoxP3 (NM_001199347.1) Forward (F), 5’-
CTGCCTTGGTACATTCGTGAAC-3’, FoxP3 Reverse
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(NM_010552.3) F, 5’-GGCTGACCCCTAAGAAACC-3’,
IL-17A R, 5’-CTGAAAATCAATAGCACGAAC-3’; β-actin
(NM_007393.3) F, 5’-CTGAAAATCAATAGCACGAAC-3’
and β-actin R, 5’-ATGGAGCCACCGATCCACA -3’. The
amplified fragments were 97, 79 and 171 base pairs (bp),
respectively. The PCRs were carried out using the
following conditions: 95°C for 15 min, followed by
40 cycles of denaturation at 95°C for 10 s, annealing at 52°C
for 30 s and extension at 72°C for 31 s (Applied Biosystems
7300, Foster, USA). The relative quantification (RQ) was
analyzed by the 2-ΔΔCt method.
Western blot analysis
Protein extraction and quantification were performed
according to the procedures specified by the manufac-
turers of the reagents used. Each sample containing
20 μg protein was separated by 5% and 10% SDS-PAGE
and electrotransferred onto polyvinylidene fluoride
membranes (Millipore, USA). The membranes were
incubated with primarily anti-IL-17A antibody (1:1,000),
anti-FoxP3 antibody (1:2,000), and rabbit polyclonal
anti-β-tubulin antibody (1:50,000) in blocking solution at
4°C overnight. Then, the membranes were incubated
with secondary goat anti-rabbit IgG (1:20,000) for
60 min and electrochemiluminescence (ECL) reagent for
1 min, followed by exposure to Kodak film (Japan). Data
were represented by the integrated optical density (IOD)Figure 2 The neurological function scores (A) and the grip strength tratio determined using analysis software ImageQuant TL
2005 image analysis software (Amersham, Biosciences,
Piscataway, NJ).
Immunohistochemical analysis
The sections were incubated with primary detection
antibody [rabbit anti-mouse IL-17A (Abcam, Cambridge,
UK, antibody concentration, 1:100), rabbit anti-mouse
FoxP3 (Abcam, Cambridge, UK, antibody concentration,
1:80)] at 4°C for 40 h. Subsequently, the sections
were incubated with the biotin-labeled secondary
antibody (sheep anti-rabbit IgG) at 37°C for 60 min.
Color development was accomplished by exposure to 3,3’-
diaminobenzidinetetrahydrochloride (DAB) for 40 seconds
to 1 min. Finally, the sections were dehydrated and
mounted for microscopic observation. Quantitative
analysis of the immunohistochemically stained images
was carried out with a NIS-Elements BR 3.0 system.
Three to five high-power fields (×400) were selected
from four sections of the lateral ventricle in each group
and positive results were expressed as IOD values.
Statistical analysis
The data were expressed as mean ± standard error (SE)
and analyzed with SPSS version 17.0 (SPSS Inc.,
Chicago, IL, USA). All the data were firstly subjected to
descriptive statistics for normality. The data with
normally distributed and equal variances were examinedest scores (B) of mice.
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wise, the data were performed with a rank-sum test. The
family-wise error rate was controlled by the statistical
method of Bonferroni. A value of p < 0.05 was considered
to indicate statistical significance.
Results
Neurological function and grip test scores
Symptoms of EAE including flaccid tail, staggering gait,
hind-limb paralysis, four-limb paralysis and even death
appeared sequentially in experimental mice from Day 8
PI. The neurological function scores of EAE mice reached
a peak on Day 16. These scores were decreased signifi-
cantly on Day 17 PI, and from Day 20 to Day 40 PI in
BSYSC-treated mice, compared to the scores in EAE mice
(p < 0.05, p < 0.01, p < 0.001, respectively; Figure 2). The
grip strength test scores of EAE mice appeared primarily
from Day 9 PI, with the falling time for EAE mice reducedFigure 3 Observation of pathological changes in the brain and spinal
Day 18 PI of EAE. NC mice showed normal structures, while EAE mice had
EAE mice exhibited a small number of inflammatory cells than EAE mice. Nto less than 30 seconds and the scores reaching a nadir on
Day 14 PI. Compared to EAE mice, the scores were
significantly higher in BSYSC-treated EAE mice from
Day 11 to Day 30 PI (p < 0.01 or p < 0.001, respectively;
Figure 2).
Pathological changes on brain and spinal cord tissues
The pathological changes in the brain and spinal cord of
mice were observed by light microscopic evaluation of
H&E stained tissues on Day 18 and Day 40 PI. The
neuronal structure was normal in the NC group. A
large number of inflammatory cells were aggregated
around small blood vessels to form “sleeve-like” structures
in the EAE model group. Conversely, treatment with PA or
BSYSC reduced inflammatory cell infiltration. The type of
inflammatory cells was classified by lymphocytes, mono-
cytes, neutrophils and eosinophils. The histopathology
scores of EAE mice were dramatically increased comparedcord of mice under the light microscope (scale bar, 20 μm) on
large amounts of inflammatory cell infiltration. PA- and BSYSC-treated
ote: ***p <0.001 vs.NC; ###p <0.001 vs. EAE.
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treatment with PA or BSYSC significantly reduced the
scores (p < 0.001; Figure 3). In further studies, the ultra-
structure of the myelin sheath and axons in the brain and
spinal cord was observed by TEM. While these were
found to be normal in NC mice, a fluffy layer, axonal
edema and disintegration were observed in the EAE mice.
Demyelination and axonal damage was ameliorated in the
PA- and BSYSC-treated EAE mice. The damage was
quantified with the ratio of area/diameter (mean) of
myelin. The results showed that the ratios of in the
brain and spinal cord of EAE mice were markedly
increased compared to those of NC mice on Day 18 and
40 PI (p < 0.05 or p < 0.001, respectively; Figure 4). The
treatment with PA or BSYSC significantly reduced the
ratios (p < 0.05, p < 0.01, p < 0.001, respectively; Figure 4).
FCM analysis of splenic CD4 + IL-17+ and CD4 +
CD25 + FoxP3+ T cells
To assess the changes in splenic Th17 and Treg cells in
EAE mice, the levels of CD4 + IL-17+ and CD4 + CD25 +
FoxP3+ T cells were measured by FCM. The ratios of
CD4 + IL-17+/CD4 + CD25 + FoxP3+ were also analyzed.
There was a significant increase in CD4 + IL-17+ cells inNC EAE
Brain
Spinal cord



























Figure 4 Pathological changes visualized under TEM on Day 18 PI (sc
had large amounts of demyelination. PA- and BSYSC-treated EAE mice exhibi
a total area of / diameter (mean) of myelin. Note: **p <0.01, ***p <0.001 VS NCthe EAE mice, compared to the NC mice on Day 6 and
Day 40 PI (p < 0.001 and p < 0.05, respectively). There
was a significant decrease in CD4 + CD25 + FoxP3+ cells
on Day 6 PI (p < 0.001), but the levels were increased on
Day 40 PI (p < 0.001). The CD4 + IL-17+/CD4 + CD25 +
FoxP3+ ratio was markedly increased only on Day 6 PI
(p < 0.001). BSYSC obviously decreased CD4 + IL-17+
levels on Day 6 and Day 40 PI compared to EAE mice
(p < 0.001 and p < 0.05, respectively). PA had similar
effects to BSYSC in lowering the CD4 + IL-17+ levels on
Day 40 PI (p < 0.01). BSYSC obviously increased CD4 +
CD25 + FoxP3+ T cell levels compared to EAE mice
on Day 6 and Day 18 PI (p < 0.001 and p < 0.05,
respectively). The CD4 + IL-17+/CD4 + CD25 + FoxP3+
ratio was significantly decreased by BSYSC treatment
during EAE induction on Days 6, 18 and 40 PI (p < 0.001,
p < 0.05, Figure 5).
ELISA analysis of inflammation-related cytokines in brain
tissue
Compared to NC mice, the levels of IL-17A, IL-6, IL-23
and TGF-β1 in the brain of EAE mice were significantly
increased at various times PI: IL-17A and IL-23 levels
on Days 6 and 18 PI (p < 0.05), IL-6 on Days 6 and 40 PIEAE+PA EAE+BSYSC









ale bar 0.5 μm). NC mice showed normal structures, while EAE mice
ted a lighter demyelination than EAE mice. The results were expressed as
; #p <0.05, ##p <0.01, ###p <0.001 VS EAE.
Figure 5 Effect of BSYSC on the expressions of CD4 + IL-17+ T cells and CD4 + CD25 + FoxP3+ T cells in the spleen of mice. It was
assessed by FCM. Note: *p <0.05, **p <0.01, ***p <0.001 VS NC;#p <0.05, ##p <0.01, ###p <0.001 VS EAE; ▲p <0.05, ▲▲p <0.01 VS EAE + PA.
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contrast, the levels of these cytokines decreased in EAE
mice treated with PA or BSYSC. Compared to EAE
mice, IL-17A was significantly decreased in PA-treated
EAE mice on Day 18 PI (p < 0.01), and in BSYSC-treated
EAE mice on Days 18 and 40 PI (p < 0.05). IL-6 was
decreased in PA-treated EAE mice on Days 18 and 40,
and in BSYSC-treated EAE mice on Days 6, 18 and 40
PI (p < 0.05 and p < 0.01). IL-23 and TGF-β1 were
decreased in PA- and BSYSC-treated EAE mice on Day
18 PI (p < 0.001 and p < 0.01, respectively; Figure 6).
qRT-PCR analysis of IL-17A and FoxP3 mRNA expression
in brain and spinal cord tissue
Compared to NC mice, IL-17A mRNA levels were
significantly increased in the brain on Day 18 PI (butnot at Day 40) and in the spinal cord on Days 18 and 40
PI in EAE mice compared to NC mice (p < 0.05, p < 0.01).
In contrast, the levels were significantly decreased in
PA- and BSYSC-treated EAE mice compared to EAE
mice in the spinal cord (p < 0.01). FoxP3 mRNA in
the spinal cord was significantly decreased in EAE
mice compared to NC mice (p < 0.001), however,
there were no differences in the levels detected in the
brain of the two groups. BSYSC increased FoxP3
mRNA levels in the spinal cord of EAE mice on Days 18
and 40 PI (p < 0.05 and p < 0.001, respectively). Analysis of
the ratio of IL-17A/FoxP3 mRNA levels revealed a signifi-
cant increase in both the brain and spinal cord on Days 18
and 40 PI in EAE mice compared to NC mice (p < 0.05 and
p < 0.001, respectively). In contrast, the ratio was signifi-
cantly decreased in spinal cord on Days 18 and 40 PI and
Figure 6 ELISA analysis of IL-17A, IL-6, IL-23 and TGF-β1 expressions in the brain of the groups. Note:*p <0.05, **p <0.01 vs. NC; #p <0.05,
##p <0.01, ###p <0.001 vs. EAE; ▲p <0.05 vs. EAE + PA.
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mice compared to EAE mice (Figure 7).
WB and IHC analysis of IL-17A and FoxP3 proteins in
brain and spinal cord tissue
WB analysis demonstrated that IL-17A protein expression
in the brain was significantly increased in EAE miceFigure 7 qRT-PCR analysis of the effect of BSYSC on mRNA expressio
Note: *p <0.05, **p <0.01, ***p <0.001 vs. NC; #p <0.05, ##p <0.01, ###p <0.001compared to NC mice on Days 18 and 40 PI (p < 0.001
and p < 0.05, respectively). In contrast, levels were signifi-
cantly reduced in the brain and spinal cord on Days 18
and 40 PI in BSYSC-treated EAE mice compared to EAE
mice (p < 0.001 and p < 0.01, respectively). In addition,
compared to NC mice, FoxP3 protein expression was
obviously decreased in the brain of EAE mice on Day 40ns of IL-17A and FoxP3 in the brain and spinal cord of mice.
vs. EAE; ▲p <0.05, ▲▲p <0.01 vs. EAE + PA.
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p < 0.001, respectively). BSYSC significantly increased
FoxP3 protein in the brain and spinal cord of EAE
mice on Days 18 and 40 PI (p < 0.01 and p < 0.001,
respectively). Furthermore, the IL-17A/FoxP3 ratios
were significantly increased in the brain and spinal
cord of EAE mice on Days 18 and 40 PI compared to
NC mice (p < 0.001 and p < 0.01 and p < 0.05, respect-
ively). In contrast, the ratios were significantly
reduced in the brain and spinal cord of BSYSC-treated
EAE mice, compared to EAE mice on Days 18 and
40 PI (p < 0.001 and p < 0.01, respectively; Figure 8).
IL-17A and FoxP3 protein expressions in the brain
and spinal cord were also detected morphologically
by IHC. The results showed that the change trends of
IL-17A and FoxP3 protein by IHC were similar to
WB (Figure 9).Figure 8 Western blot analysis of the effect of BSYSC on IL-17A and F
(A) to (D) NC, EAE, EAE + PA and EAE + BSYSC mice. Note: *p <0.05, **p <0.0
▲▲▲p <0.001 vs. EAE + PA.Discussion
The results of this study showed the EAE induced by
administration of MOG35–55 was pathologically character-
ized by mononuclear cells infiltration, cells shrinkage and
nucleuses lysogenic, with neurological deficits associating
with demyelination occurred in the brain and spinal cord,
which are consistent with previous reports [25]. Comparing
with EAE, the EAE + BSYSC manifested an improved
neurological function, ameliorated inflammation and de-
myelination in the CNS. Combining with our previous
studies [26], these observations suggested that BSYSC had
the neuroprotective effects in EAE mice.
To analyze the neuroprotective mechanisms of BSYSC,
we first investigated the development of Th17 and Treg
responses in the EAE spleen. It is worth noting that the
ratio of CD4 + IL-17+ and CD4 + CD25 + FoxP3 + T cells
was obviously increased on Day 6 PI in the spleen ofoxP3 protein expressions in the brain and spinal cord of mice.
1, ***p <0.001 vs. NC; #p <0.05, ##p <0.01, ###p <0.001 vs. EAE; ▲p <0.05,
Figure 9 IHC analysis of the effect of BSYSC on IL-17A and FoxP3 protein expressions in the brain and spinal cord of mice. Note: **p <0.01,
***p <0.001 vs. NC; #p <0.05, ##p <0.01, ###p <0.001 vs. EAE.
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IL-17A-secreting PLP-specific CD4+ T cells, measured
by enzyme-linked immunospot assay (ELISPOT),
increased significantly in the spleen of SJL mice on Day 8
and in the CNS on Day 25 following the induction of EAE
by PLP139–151 administration [27]. It was indicated that
the inflammation reaction was initiated in the peripheral
immune organs in the early stage, producing cytokines
that disrupt the blood brain barrier (BBB) and allowing
immune cells to enter the CNS. Thus, CNS damage
occurs as a consequence of peripheral immune responses
[28]. Further studies demonstrated that the early treat-
ment with Fasudil, a selective Rho kinase (ROCK) inhibi-
tor, resulted in down-regulation of CD4 + IL-17+ T cells in
the spleen on Day 9 PI [29]. In our study, BSYSC signifi-
cantly regulated the balance between the Th17 and Treg
T cells in the spleen of EAE mice in the early stage,resulting in a reduction in the inflammatory responses in
peripheral immune organs.
Moreover, we found the levels of inflammation-related
cytokines, such as IL-17A, IL-6 and IL-23 increased dur-
ing the entire course of the disease in the brain of EAE
mice. IL-17A, the predominant functional member of the
IL-17 family, is a pro-inflammatory cytokine produced by
Th17 cells [30]. IL-6 is strongly induced by cells of the
innate immune system [31]. Studies have shown that
the expressions of these two cytokines are significantly
increased in MS/EAE [32,33]. IL-23 is an important factor
in Th17 differentiation and the development of EAE [34]
and studies have shown that IL-23 and IL-17 secreting
cells are attacked to the CNS, leading to demyelination
[35,36]. Both PA and BSYSC down regulated the expres-
sions of IL-17A, IL-6 and IL-23 at different stage of EAE,
especially in the acute stage.
Zheng et al. BMC Complementary and Alternative Medicine  (2015) 15:60 Page 12 of 14TGF-β1 has been reported to stimulate naïve CD4+ T
cells to differentiate into Treg cells which also pro-
duce TGF-β1 [37]. Although TGF-β1 exerts an anti-
inflammatory activity via the induction of FoxP3 expression,
in combining with IL-6 and IL-23, TGF-β1 stimulates the
production of Th17 cells in EAE [38,39]. In the present
study, the high TGF-β1 level in the brain can be speculated
to the induction of Th17 cell differentiation by the combin-
ation of IL-6 and IL-23, resulting in the exacerbation of
EAE [40]. This is supported by the observation that BSYSC
reduced not only the levels of IL-17A, IL-6 and IL-23, but
also of TGF-β1.
Finally, we targeted the regulatory role of BSYSC
played on the IL-17A/FoxP3 ratio in the brain and spinal
cord in EAE mice. IL-17A acts an encephalitogenic part
in the EAE model, with accumulation of Th17 cells and
elevation of IL-17A levels observed in the brain and
spinal cord of EAE mice [41,42]. Furthermore, mice
lacking Treg cells but having MBP-specific effector T
cells can develop spontaneous EAE [43]. In previous
literature, immune dysfunction is related with the up-
regulation of Th17 cells and down-regulation of the Treg
cells [40,44]. Therefore, the regulation of immunity
balance between Th17 and Treg cells is implicated as
novel drug targets for the treatment of MS. Recently, the
neuroprotective effect against EAE with electroacupunc-
ture (EA) was reported, the regulation of Th1/Th2/Th17/
Treg by EA was observed as well [45]. However, few
studies have investigated the effects of formulas in
different tissues and during different stages of EAE.
In this study, we found that BSYSC regulated the balance
between IL-17A and FoxP3 mRNA and protein expression
in the CNS of EAE mice.
Meanwhile, the 8 chemical components of BSYSC were
identified. Several studies indicates thatiridoids (loganic
acid), phenylpropanoids (decaffeoyl verbascoside, acteoside,
isoacteoside and forsythiaside), flavonoids (kaempferol-3-
O-α-L-rhamnoside and Isorhamnetin-3-O-rutinoside) pos-
sess anti-inflammatory, anti-oxidative, immune-regulating
and neuroprotective effects [46-52]. Additionally, some of
the herbs in BSYSC, such as Radix Rehmanniae, Radix
Polygoni Multiflori and Fructus Forsythiae Suspensae also
have the above effects [53-59]. These findings implied the
effects of BSYSC in MS/EAE were considered to be related
to the entire interactive action of multiple components
and herbs.
Conclusion
In this study, BSYSC exerts significant neuroprotective
effects against EAE in mice. The mechanism is related to
the decreased number of lymphocytes in the peripheral
inflammatory system, thereby reducing the entry of
cytotoxic T cells into CNS, and mediating regulation of
Th17 and Treg cells and the related cytokines in the CNS.This study provides a basis for further research into the
efficacy of BSYSC and its active ingredients in the
treatment of MS. However, the formula contained
within BSYSC is complicated and the components
exert multi-target effects, thus, the other mechanisms by
which BSYSC influences disease in EAE mice remain
poorly understood and require further investigation.
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